Quick Answer
Vor Biopharma Inc. reported Net Income of -$695.98 million for fiscal year 2025.
Vor Biopharma Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$695.98M -495.3% |
-$116.91M +0.8% |
-$117.86M -28.0% |
-$92.09M -33.7% |
-$68.90M -59.0% |
-$43.34M |
| Diluted EPS | -$70.50 -107.2% |
-$34.03 -1844.6% |
-$1.75 +24.9% |
-$2.33 -11.0% |
-$2.10 | — |
| Total Assets | $464.13M +224.8% |
$142.89M -27.9% |
$198.13M -33.8% |
$299.37M +23.4% |
$242.59M +219.6% |
$75.91M |
| Cash and Equivalents | $396.49M +383.8% |
$81.95M +161.3% |
$31.36M -45.7% |
$57.71M -51.8% |
$119.80M +146.8% |
$48.54M |
| Stockholders Equity | -$164.31M -270.0% |
$96.66M -35.9% |
$150.72M -39.9% |
$250.61M +15.9% |
$216.26M +466.1% |
-$59.06M -238.9% |
| R&D Expense | $321.53M +244.6% |
$93.31M -1.1% |
$94.31M +46.1% |
$64.55M +35.8% |
$47.53M +50.3% |
$31.62M |
| Operating Income | -$371.64M -206.7% |
-$121.19M +3.8% |
-$126.04M -34.9% |
-$93.42M -35.4% |
-$69.02M -59.2% |
-$43.37M |
| Shares Outstanding | 38.72M +520.6% |
6.24M -90.8% |
67.89M +2.9% |
66.00M +77.5% |
37.17M +7260.3% |
505,074 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$812.68M | -2848.9% | +48.4% |
| Diluted EPS | September 30, 2025 | -$121.63 | -1410.9% | -868.4% |
| Total Assets | September 30, 2025 | $176.24M | +51.9% | -14.2% |
| Cash and Equivalents | September 30, 2025 | $160.46M | +203.9% | -15.8% |
| Stockholders Equity | September 30, 2025 | -$2.23B | -3150.5% | -47.8% |
| R&D Expense | September 30, 2025 | $14.14M | -35.2% | -94.6% |
| Operating Income | September 30, 2025 | -$28.11M | +1.4% | +89.8% |
| Shares Outstanding | September 30, 2025 | 9.03M | -86.9% | -92.8% |
- Vor Biopharma Inc. reported Net Income of -$695.98 million for fiscal year 2025.
- Vor Biopharma Inc. showed a decrease of -495.3% in Net Income compared to the prior fiscal year.
- Vor Biopharma Inc. reported Diluted EPS of $70.50 per share (loss) for fiscal year 2025.
- Vor Biopharma Inc. showed a decrease of -107.2% in Diluted EPS compared to the prior fiscal year.
- Vor Biopharma Inc. reported Total Assets of $464.13 million for fiscal year 2025.
- Vor Biopharma Inc. showed an increase of +224.8% in Total Assets compared to the prior fiscal year.
- Vor Biopharma Inc. reported Cash and Equivalents of $396.49 million for fiscal year 2025.
- Vor Biopharma Inc. showed an increase of +383.8% in Cash and Equivalents compared to the prior fiscal year.
- Vor Biopharma Inc. reported Stockholders Equity of -$164.31 million for fiscal year 2025.
- Vor Biopharma Inc. showed a decrease of -270.0% in Stockholders Equity compared to the prior fiscal year.
- Vor Biopharma Inc. reported R&D Expense of $321.53 million for fiscal year 2025.
- Vor Biopharma Inc. showed an increase of +244.6% in R&D Expense compared to the prior fiscal year.
- Vor Biopharma Inc. reported Operating Income of -$371.64 million for fiscal year 2025.
- Vor Biopharma Inc. showed a decrease of -206.7% in Operating Income compared to the prior fiscal year.
- Vor Biopharma Inc. reported Shares Outstanding of 38.72 million shares for fiscal year 2025.
- Vor Biopharma Inc. showed an increase of +520.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: